Patriots Take Chance on Marcus Cannon Despite Lymphoma

Two days after receiving his first chemotherapy treatment for non-Hodgkin’s lymphoma, TCU offensive lineman Marcus Cannon was drafted by the New England Patriots.

When he originally arrived at the NFL combine in February, Cannon had no idea of the dramatic journey that lay ahead for him. Considered a top-rated draft prospect coming into the draft, the TCU’s star had his world turned upside down when a biopsy that revealed all wasn’t well.

Almost immediately upon receiving his non-Hodgkin’s lymphoma diagnosis, Cannon noticed teams turning away. His impressive showing alongside quarterback Andy Dalton as TCU defeated Wisconsin in the Rose Bowl en route to a 13-0 year seemed to no longer matter. Neither that nor him allowing zero sacks in the last two years was enough to save him from the dreaded “sick” label pasted onto him by GMs and teams.

Originally projected to go in the second or third rounds, Cannon fell all the way to the fifth round before being selected by the Patriots on Saturday. Not that the 22-year-old was complaining, of course.

"Me and my family were pretty ecstatic," he said. "After all that we figured out in the last couple of weeks, it's a blessing to have this opportunity to play in the NFL."

New England selected Cannon with the vision of playing him at guard, despite the fact that he served as a tackle in college. The hope is that he can fill the gap left behind by the retirement of Stephen Neal.

"He's a very highly rated player," said coach Bill Belichick. "We're comfortable with the situation and all that it entails."

The Patriots took Cannon wit the 10th pick of the fifth round, 138th pick overall.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap